, - ,
Retinoic acid and TGF- signalling cooperate to overcome MYCN-induced retinoid resistance
Clin Med (Lond) 16(3):262266 Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E (2015) American association of clinical endocrinologists, American college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndromePart 1
The notable peptide vaccines that have undergone phase I/II/III clinical trials include HER-2/neu immunodominant peptide (lung, breast, or ovarian cancer) [6971], Mucin-1 (MUC-1, Stimuvax), peptide (breast or colon cancer) [72, 73], Carcinoembryonic antigen (colorectal, gastric, breast, pancreatic and non-small-cell lung cancers) [74, 75], Prostate-specific membrane antigen (prostate cancer) [7678], HPV-16 E7 peptide (cervical cancer) [79], Ras oncoprotein peptide (colorectal and pancreatic carcinomas) [8082], and Melanoma antigens (Melanoma) [62, 68, 8385]
